- Delpharm’s Évreux site obtained ANVISA certification in March, issued by Brazil’s health authority.
- The approval enables access to the Brazilian market and supports global exports of solid dosage forms.
Delpharm has obtained ANVISA certification for its Évreux site in March, marking a step in expanding its international operations. The certification was issued by Brazil’s health authority and applies to the site’s manufacturing of solid dosage forms.
The approval enables the Évreux facility to access the Brazilian market, which is among the largest in Latin America. The certification confirms that the site meets required quality standards for the production of solid dosage pharmaceuticals.
The Évreux site focuses on solid dosage forms and supports global export activities. According to the company, the facility is backed by dedicated teams responsible for maintaining manufacturing quality standards, aligning with expectations for CDMO and contract manufacturing operations.
